Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | APAF1 | O14727 | 1/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.49 |
| ▸ | PTPRC | P08575 | 3/20 | 0.47 |
| ▸ | CDC25B | P30305 | 3/20 | 0.47 |
| ▸ | PTPRF | P10586 | 2/20 | 0.47 |
| ▸ | SOAT1 | P35610 | 3/20 | 0.46 |
| ▸ | S100A4 | P26447 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15764225 | 0.83 | BACE1 (0.68) | BACE1ALDH1A1MAPTLMNAMAPK1 | |
| SCHEMBL28865245 | 0.83 | BACE1 (0.66) | BACE1ALDH1A1MAPTLMNAMAPK1 | |
| SCHEMBL11048150 | 0.81 | BACE1 (0.72) | BACE1ALDH1A1MAPTLMNAMAPK1 | |
| SCHEMBL5485068 | 0.80 | BACE1 (1.00) | BACE1ALDH1A1MAPTLMNAMAPK1 | |
| SCHEMBL29673492 | 0.80 | BACE1 (1.00) | BACE1ALDH1A1MAPTLMNAMAPK1 | |
| SCHEMBL28121286 | 0.80 | BACE1 (0.60) | BACE1ALDH1A1MAPTLMNAMAPK1 | |
| SCHEMBL6688709 | 0.80 | BACE1 (0.60) | BACE1ALDH1A1MAPTLMNAMAPK1 | |
| SCHEMBL25834756 | 0.79 | BACE1 (0.75) | BACE1ALDH1A1MAPTLMNAMAPK1 | |
| Methylamine SCHEMBL3277347 | 0.79 | BACE1 (0.89) | BACE1ALDH1A1MAPTLMNAMAPK1 | |
| SCHEMBL31423340 | 0.77 | BACE1 (1.00) | BACE1ALDH1A1MAPTLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012079032-A2 | COMPOSITIONS AND METHODS OF TREATING DRUG-RESISTANT RETROVIRAL INFECTIONS | TRANA DISCOVERY, INC. (US) | 2012-06-14 | — | — | WO | claimed |
| WO-2011113060-A2 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| US-20190022100-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY INC (US) | 2019-01-24 | — | — | US | disclosed |
| US-10098887-B2 | Antiviral compounds and methods of use thereof | TRANA DISCOVERY, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20160129006-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY INC (US) | 2016-05-12 | — | — | US | disclosed |
| US-9173886-B2 | Antiviral compounds and methods of use thereof | TRANA DISCOVERY, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130071353-A1 | Antiviral Compounds and Methods of Use Thereof | TRANA DISCOVERY, INC (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2012079032-A2 | COMPOSITIONS AND METHODS OF TREATING DRUG-RESISTANT RETROVIRAL INFECTIONS | TRANA DISCOVERY, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2011113060-A2 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10098887-B2 | Antiviral compounds and methods of use thereof | TYMP, MAVS, ZC3HAV1 | BACE1 1631/4885ALDH1A1 2506/4885MAPT 3443/4885 |
| US-20160129006-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TYMP, MAVS, ZC3HAV1 | BACE1 1631/4885ALDH1A1 2506/4885MAPT 3443/4885 |
| US-20130071353-A1 | Antiviral Compounds and Methods of Use Thereof | TYMP, MAVS, ZC3HAV1 | BACE1 1631/4885ALDH1A1 2506/4885MAPT 3443/4885 |
| US-20190022100-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TYMP, MAVS, ZC3HAV1 | BACE1 1631/4885ALDH1A1 2506/4885MAPT 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.